ArticleJournal of medical virology2025
In Vitro Synergistic Antiviral Effects of β-D-N4-hydroxycytidine and Teriflunomide in Combination against a Broad Range of RNA Viruses.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- West Nile Neuroinvasive Disease: Current Management, Emerging Therapies and Future Clinical Trial Priorities.Reviews in medical virology · 2026Review
- c-Met inhibitor NVP-BVU972 induces antiviral protection and suppresses NF-κB-mediated inflammation.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Emerging and important endemic viral diseases without effective antiviral are important public health threat. An effective broad-spectrum antiviral can be a pivotal tool to mitigate future epidemics and provide a solution for endemic viral diseases. Molnupiravir, a pyrimidine analog, is known for the COVID-19 treatment. It has been shown to inhibit a broad range of RNA viruses. Inhibition of de novo pyrimidine synthesis by teriflunomide, a dihydroorotate dehydrogenase inhibitor, also showed potent antiviral activity against various RNA viruses. Mechanistically, pyrimidine synthesis inhibition should enhance the activity of molnupiravir as it reduces competition of native nucleotides to incorporate into nascent viral RNA. Molnupiravir and teriflunomide combination has been recently shown to have synergistic effect against SARS-CoV-2. Here we show that the combination of β-D-N4-hydroxycytidine, the active form of molnupiravir, and teriflunomide also showed synergistic activity against many RNA viruses. This combination may offer an effective antiviral regimen not only for future emerging viral diseases but also existing important viral diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.